Synthetic introns enable mutation-dependent targeting of cancer cells
UID: 10888
- Description
- Summary from GEO:
"Many cancers carry recurrent change-of-function mutations in RNA splicing factor genes, which induce sequence-specific changes in RNA splicing. Here, we describe a method to harness this change in RNA splicing activity to drive splicing factor mutation-dependent gene expression in cancers and selectively eliminate these tumors. We engineered synthetic introns which were efficiently spliced in leukemia and breast epithelial cells bearing the most common SF3B1 mutations, but unspliced in wild-type cells—and vice versa—to yield mutation-dependent protein production. A massively parallel screen of 8,881 distinct introns delineated ideal intronic size, mapped essential sequence elements, and revealed the basis of mutation-dependent splicing. Synthetic introns enabled mutation-dependent expression of herpes simplex virus thymidine kinase and subsequent ganciclovir-mediated elimination of leukemia and breast epithelial cells bearing SF3B1 mutations, while leaving wild-type cells unaffected. This approach significantly decreased the growth of otherwise lethal leukemia xenografts and correspondingly improved host survival. The modular, compact, and specific nature of synthetic introns thereby provide a means to exploit cancer-specific changes in RNA splicing for genotype-dependent gene expression and gene therapy."
Overall design from GEO:
"Analysis of synthetic intron splicing in SF3B1 MUT vs SF3B1 WT cells."
-
Access via GEO
Accession #: GSE163217Access via BioProject
Accession #: PRJNA685220Access via SRA
Accession #: SRP297952 - Access Restrictions
-
Free to All
- Access Instructions
- The NCBI Gene Expression Omnibus, BioProject, and SRA databases provides open access to these files.
- Associated Publications
- Equipment Used
- Dataset Format(s)
- CSV
- Dataset Size
- 594.6 KB (CSV), 425 B (CSV)
Do you have or know of a dataset that should be added to the catalog? Let us know!